Production (Stage)
Neuphoria Therapeutics Inc.
NEUP
$6.87
-$0.28-3.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -- | -- | -- | 28.01% | 5.91% |
| Total Depreciation and Amortization | -- | -- | -- | 24.97% | 13.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | -- | -71.47% | -104.42% |
| Change in Net Operating Assets | -- | -- | -- | -101.63% | 413.15% |
| Cash from Operations | -- | -- | -- | 2.90% | -18.21% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -17,925.00% | -194.64% |
| Cash from Investing | -- | -- | -- | -35,350.00% | -195.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 208.02% | 129.16% |
| Issuance of Common Stock | -- | -- | -- | 38.66% | -6.76% |
| Repurchase of Common Stock | -- | -- | -- | -- | 3.33% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 515.37% | 75.41% |
| Cash from Financing | -- | -- | -- | 205.75% | 65.59% |
| Foreign Exchange rate Adjustments | -- | -- | -- | 167.98% | 49.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -- | -- | 79.18% | 7.45% |